-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer announced today that the U.
S.
FDA has approved Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for use in adults 18 years and older to prevent invasive diseases and pneumonia caused by the 20 pneumococcal serotypes in the vaccine
.
The press release stated that this is the first approved vaccine against 20 pneumococcal serotypes that cause most aggressive diseases and pneumonia, including 7 serotypes that cause 40% of pneumococcal disease cases and deaths in the United States
.
Pfizer's clinical programs in adults include phase 1 and phase 2 clinical trials, as well as 3 phase 3 clinical trials describing vaccine safety and evaluating immunogenicity
.
More than 6000 adult subjects 18 years and older participated in three phase 3 trials, including adults 65 years and older, unvaccinated adults, and adults who had previously been vaccinated against pneumococcal vaccine